AUTHOR=Liu Chenglong , Yang Mengxuan , Zhang Daizhou , Chen Ming , Zhu Di 

TITLE=Clinical cancer immunotherapy: Current progress and prospects

JOURNAL=Frontiers in Immunology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.961805

DOI=10.3389/fimmu.2022.961805

ISSN=1664-3224

ABSTRACT=<p>Immune checkpoint therapy <italic>via</italic> PD-1 antibodies has shown exciting clinical value and robust therapeutic potential in clinical practice. It can significantly improve progression-free survival and overall survival. Following surgery, radiotherapy, chemotherapy, and targeted therapy, cancer treatment has now entered the age of immunotherapy. Although cancer immunotherapy has shown remarkable efficacy, it also suffers from limitations such as irAEs, cytokine storm, low response rate, etc. In this review, we discuss the basic classification, research progress, and limitations of cancer immunotherapy. Besides, by combining cancer immunotherapy resistance mechanism with analysis of combination therapy, we give our insights into the development of new anticancer immunotherapy strategies.</p>